Delta-Fly Pharma, Inc.

4598

JP3549370009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 07:00:00 15/05/2024 BST			5-day change	1st Jan Change
715 ^JPY	-3.38%		-1.92%	-29.56%

04-08	Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	CI
03-11	Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	CI

Delta-Fly Pharma, Inc. announced that it has received funding from Sanyo Chemical Industries Ltd.

March 22, 2018

Delta-Fly Pharma, Inc. announced that it has received funding from new investor Sanyo Chemical Industries Ltd. (TSE:4471) on March 23, 2018.

Latest news about Delta-Fly Pharma, Inc.

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax	04-08	CI
Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax in the AML Patients Treated by VTX in the AML	03-11	CI
Delta-Fly Pharma Inc. Announces Abstracts Submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO Annual Meeting	02-07	CI
Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323	02-02	CI
Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML	01-30	CI
Delta-Fly Pharma, Inc. announced that it has received ¥503.7238 million in funding from Nippon Chemiphar Co., Ltd.	11-09	CI
Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited	04/12/22	CI
Delta-Fly Pharma, Inc. announced that it expects to receive Ã‘1.300842 billion in funding from Macquarie Group Limited	16/11/22	CI
Delta-Fly Pharma, Inc. announced that it has received ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	23/12/20	CI
Delta-Fly Pharma, Inc. announced that it expects to receive ¥5.67 million in funding from Mizuho Securities Co., Ltd., Investment Arm	07/12/20	CI
Delta-Fly Pharma Enters into Licensing Agreement with Nippon Chemifa	23/03/20	CI
Delta-Fly Pharma, Inc. Initiates Phase 3 Clinical Study of DFP-10917 and Phase 1 Clinical Study of DFP-14927	26/11/19	CI
Certain Common Shares of Delta-Fly Pharma, Inc. are subject to a Lock-Up Agreement Ending on 9-JAN-2019.	08/01/19	CI
Delta-Fly Pharma, Inc. has completed an IPO in the amount of ¥3.339 billion.	11/10/18	CI
Delta-Fly Pharma, Inc. has filed an IPO.	05/09/18	CI
Delta-Fly Pharma, Inc. announced that it has received funding from Sanyo Chemical Industries Ltd.	22/03/18	CI

Delta-Fly Pharma, Inc. is a Japan-based company principally engaged in the research, development, manufacture and sale of pharmaceuticals. The Company's development pipeline includes anticancer drug candidate compound DFP-10917 whose target disease is refractory or recurrent acute myelogenous leukemia, anticancer drug candidate compound DFP-14323 whose target disease is lung cancer, anti-cancer drug candidate compound DFP-11207 whose target disease is solid cancer, anticancer drug candidate compound DFP-14927 whose target disease is solid cancer or blood cancer, anticancer drug candidate compound DFP-10825 whose target disease is peritoneal dissemination metastatic cancer.

Sector

Pharmaceuticals

Calendar

14/05/2024 - Q4 2023 Earnings Release

More about the company

	1st Jan change	Capi.
DELTA-FLY PHARMA, INC.	-29.56%	38.93M
NOVO NORDISK A/S	+31.26%	588B
JOHNSON & JOHNSON	-3.39%	364B
MERCK & CO., INC.	+19.45%	326B
ABBVIE INC.	+5.08%	285B
ASTRAZENECA PLC	+15.51%	239B
NOVARTIS AG	+10.04%	210B
ROCHE HOLDING AG	-7.08%	200B
AMGEN INC.	+9.24%	167B
PFIZER, INC.	-0.47%	161B

Other Pharmaceuticals